#United States #New York #Class Action #Rosen Law Firm #Immutep Ltd.

Overview of the Class Action Lawsuit

Rosen Law Firm, a renowned global investor rights attorney, has initiated a class action lawsuit for individuals who purchased American Depositary Receipts (ADRs) of Immutep Ltd. (NASDAQ: IMMP) during the specific period from March 24, 2025, to March 12, 2026. This move marks a critical opportunity for investors who feel they were misled by the company's communications regarding its clinical trials and the performance of its candidate drugs.

Timeline for Involvement

Potential plaintiffs interested in leading this class action must act swiftly, as the deadline to file is set for July 6, 2026. This deadline emphasizes the urgency for stakeholders to come forward if they seek to mandate the litigation process. Those included in the class are not liable for any costs out of pocket since the legal representation is arranged under a contingency fee basis.

Details of the Allegations

The lawsuit asserts that throughout the stated Class Period, the defendants, presumably key figures within Immutep, made false and misleading statements regarding the status and potential of the TACTI004 trial. These misrepresentations reportedly stemmed from overconfidence in the efficacy and safety assessments of their drug, eftilagimod alfa, especially following promising results of prior studies, specifically the TACTI-002 and INSIGHT-003 trials.

In a critical disclosure made on January 30, 2026, the defendants indicated to the public that the trial was demonstrating "strong operational progress," which was purportedly on target for a planned interim review in the first quarter of 2026. However, the lawsuit suggests that inside knowledge—aided by access to detailed clinical data—likely indicated otherwise, unveiling risks that the trial might not meet its primary efficacy or safety endpoints.

Investor Rights and Legal Representation

For investors seeking more information on how to join the class action or if they wish to serve as a lead plaintiff, the Rosen Law Firm has laid out clear instructions. Interested parties can visit the firm's website or reach legal counsel directly via phone or email. It’s vital to note that while a class has not yet been certified, all participants still maintain a right to seek independent counsel.

The legal team emphasizes the importance of selecting qualified attorneys who possess a proven success record in handling securities class actions. The Rosen Law Firm has established itself as a reputable force within this field, having secured notable settlements on behalf of investors facing similar challenges.

The Broader Impact on Investors

With such legal proceedings, there is significant potential for recovering losses associated with stock price drops resulting from the alleged deceptive practices. For individuals who purchased Immutep’s ADRs during the Class Period, joining this class action could lead to potential compensation if the court rules in favor of the investors.

Final Thoughts

Investors are encouraged to keep abreast of developments related to this class action by following Rossen Law Firm on their social media platforms. The outcome may not only impact those directly involved but could also set precedents affecting similar future investor rights cases. Given the complexities involved, it is essential for every individual concerned about potential losses to assess their options carefully and take timely action for participation in this significant legal initiative.